Whether clinical endpoints such as secondary infection rates are affected by therapeutical application of GM-CSF is under research (NCT02361528).However, smaller studies showed promising results with lower infection rates [88] or shorter duration of infection in immunosuppressed critically ill patients treated with GM-CSF. Here, CSF2 is linked to infection.